In vitro and in vivo characterization of recombinant Ebola viruses expressing enhanced green fluorescent protein

Journal of Infectious Diseases

Volumn 196, Issue SUPPL. 2, 2007, Pages

  Ebihara, Hideki ^a,b,c,d,i   Theriault, Steven ^d,e   Neumann, Gabriele ^f   Alimonti, Judie B ^d   Geisbert, Joan B ^g   Hensley, Lisa E ^g   Groseth, Allison ^d,e   Jones, Steven M ^e   Geisbert, Thomas W ^h   Kawaoka, Yoshihiro ^a,b,c,f   Feldmann, Heinz ^d,e,i  

^a International Research Center for Infectious Diseases   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

^d PUBLIC HEALTH AGENCY OF CANADA   (Canada)

^e UNIVERSITY OF MANITOBA   (Canada)

^f UNIVERSITY OF WISCONSIN MADISON   (United States)

^g UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^h NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

ⁱ PUBLIC HEALTH AGENCY OF CANADA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ENHANCED GREEN FLUORESCENT PROTEIN; NUCLEOPROTEIN; PROTEIN VP24; PROTEIN VP35; UNCLASSIFIED DRUG; VIRUS PROTEIN; GREEN FLUORESCENT PROTEIN; RECOMBINANT PROTEIN;

ANIMAL CELL; CONFERENCE PAPER; CONTROLLED STUDY; EBOLA VIRUS; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; ANIMAL; ARTICLE; CELL CULTURE; CELL STRAIN U937; CERCOPITHECUS; DEMOCRATIC REPUBLIC CONGO; GENETIC RECOMBINATION; GENETIC TRANSFECTION; GENETICS; HAPLORHINI; MACROPHAGE; MOLECULAR CLONING; NUCLEOTIDE SEQUENCE; ULTRASTRUCTURE; VERO CELL; VIROLOGY;

ANIMALS; BASE SEQUENCE; CELLS, CULTURED; CERCOPITHECUS AETHIOPS; CLONING, MOLECULAR; DEMOCRATIC REPUBLIC OF THE CONGO; EBOLAVIRUS; GREEN FLUORESCENT PROTEINS; HAPLORHINI; HUMANS; MACROPHAGES; RECOMBINANT PROTEINS; RECOMBINATION, GENETIC; TRANSFECTION; U937 CELLS; VERO CELLS;

EID: 38449123733     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/520590     Document Type: Conference Paper

References (46)

1. Ebihara H, Groseth A, Neumann G, Kawaoka Y, Feldmann H. The role of reverse genetics systems in studying viral hemorrhagic fevers [review]. Thromb Haemost 2005; 94:240-53.
2. Rudd PA, Cattaneo R, von Messling V. Canine distemper virus uses both the anterograde and the hematogenous pathway for neuroinvasion. J Virol 2006; 80:9361-70.
3. von Messling V, Milosevic D, Cattaneo R. Tropism illuminated: lymphocyte-based pathways blazed by lethal morbillivirus through the host immune system. Proc Natl Acad Sci USA 2004; 101:14216-21.
4. Towner JS, Paragas J, Dover JE, et al. Generation of eGFP expressing recombinant Zaire ebolavirus for analysis of early pathogenesis events and high-throughput antiviral drug screening. Virology 2005; 332:20-7.
5. Jones SM, Feldmann H, Stroher U, et al. Live attenuated recombinant vaccine platform protects non-human primates against lethal challenge with either Ebola virus or Marburg virus. Nature Med 2005; 11:786-90.
6. Geisbert TW, Jones S, Fritz EA, et al. Development of a new vaccine for the prevention of Lassa fever. PLoS Med 2005; 2:e183.
7. Hevey M, Negley D, Pushko P, Smith J, Schmaljohn A. Marburg virus vaccines based upon alphavirus replicons protect guinea pigs and nonhuman primates. Virology 1998; 251:28-37.
8. Enterlein S, Volchkov V, Weik M, et al. Rescue of recombinant Marburg virus from cDNA is dependent on nucleocapsid protein VP30. J Virol 2006; 80:1038-43.
9. Neumann G, Feldmann H, Watanabe S, Lukashevich I, Kawaoka Y. Reverse genetics demonstrates that proteolytic processing of the Ebola virus glycoprotein is not essential for replication in cell culture. J Virol 2002; 76:406-10.
10. Muhlberger E, Lotfering B, Klenk HD, Becker S. Three of the four nucleocapsid proteins of Marburg virus, NP, VP35, and L, are sufficient to mediate replication and transcription of Marburg virus-specific monocistronic minigenomes. J Virol 1998; 72:8756-64.
11. Muhlberger E, Weik M, Volchkov VE, Klenk HD, Becker S. Comparison of the transcription and replication strategies of Marburg virus and Ebola virus by using artificial replication systems. J Virol 1999; 73:2333-42.
12. Volchkov VE, Volchkova VA, Muhlberger E, et al. Recovery of infectious Ebola virus from complementary DNA: RNA editing of the GP gene and viral cytotoxicity. Science 2001; 291:1965-9.
13. Ebihara H, Takada A, Kobasa D, et al. Molecular determinants of Ebola virus virulence in mice. PLoS Pathog 2006; 2:e73.
14. Hartman AL, Dover JE, Towner JS, Nichol ST. Reverse genetic generation of recombinant Zaire Ebola viruses containing disrupted IRF-3 inhibitory domains results in attenuated virus growth in vitro and higher levels of IRF-3 activation without inhibiting viral transcription or replication. J Virol 2006; 80:6430-40.
15. Neumann G, Ebihara H, Takada A, et al. Ebola virus VP40 late domains are not essential for viral replication in cell culture. J Virol 2005; 79:10300-7.
16. Neumann G, Geisbert TW, Ebihara H, et al. Proteolytic processing of Ebola virus glycoprotein is not critical for Ebola virus replication in nonhuman primates. J Virol 2007; 81:2995-8.
17. Takada A, Ebihara H, Jones S, Feldmann H, Kawaoka Y. Protective efficacy of neutralizing antibodies against Ebola virus infection. Vaccine 2006; 25:993-9.
18. Takada A, Feldmann H, Ksiazek TG, Kawaoka Y. Antibody-dependent enhancement of Ebola virus infection. J Virol 2003; 77:7539-44.
19. Geisbert TW, Hensley LE, Larsen T, et al. Pathogenesis of Ebola hemorrhagic fever in cynomolgus macaques: evidence that dendritic cells are early and sustained targets of infection. Am J Pathol 2003; 163:2347-70.
20. Committee on the Care and Use of Laboratory Animals of the Institute of Laboratory Animals Resources Commission of Life Sciences, National Research Council. Guide for the care and use of laboratory animals. Washington, DC: National Academy Press, 1996.
21. Bray M. The role of the type I interferon response in the resistance of mice to filovirus infection. J Gen Virol 2001; 82:1365-73.
22. Schindler C, Darnell JE Jr. Transcriptional responses to polypeptide ligands: the JAK-STAT pathway [review]. Annu Rev Biochem 1995; 64:621-51.
23. Durbin JE, Hackenmiller R, Simon MC, Levy DE. Targeted disruption of the mouse Stat1 gene results in compromised innate immunity to viral disease. Cell 1996; 84:443-50.
24. Garcia-Sastre A, Durbin RK, Zheng H, et al. The role of interferon in influenza virus tissue tropism. J Virol 1998; 72:8550-8.
25. Bray M, Davis K, Geisbert T, Schmaljohn C, Huggins J. A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever. J Infect Dis 1998; 178:651-61.
26. Geisbert TW, Hensley LE. Ebola virus: new insights into disease aetiopathology and possible therapeutic interventions. Expert Rev Mol Med 2004; 6:1-24.
27. Geisbert TW, Young HA, Jahrling PB, Davis KJ, Kagan E, Hensley LE. Mechanisms underlying coagulation abnormalities in Ebola hemorrhagic fever: overexpression of tissue factor in primate monocytes/macrophages is a key event. J Infect Dis 2003; 188:1618-29.
28. Hashimoto K, Ono N, Tatsuo H, et al. SLAM (CD150)-independent measles virus entry as revealed by recombinant virus expressing green fluorescent protein. J Virol 2002; 76:6743-9.
29. Quinones-Kochs MI, Schnell MJ, Buonocore L, Rose JK. Mechanisms of loss of foreign gene expression in recombinant vesicular stomatitis viruses. Virology 2001; 287:427-35.
30. He B, Paterson RG, Ward CD, Lamb RA. Recovery of infectious SV5 from cloned DNA and expression of a foreign gene. Virology 1997; 237:249-60.
31. Tokusumi T, Iida A, Hirata T, Kato A, Nagai Y, Hasegawa M. Recombinant Sendai viruses expressing different levels of a foreign reporter gene. Virus Res 2002; 86:33-8.
32. Wertz GW, Moudy R, Ball LA. Adding genes to the RNA genome of vesicular stomatitis virus: positional effects on stability of expression. J Virol 2002; 76:7642-50.
33. Cattaneo R, Rebmann G, Schmid A, Baczko K, ter Meulen V, Billeter MA. Altered transcription of a defective measles virus genome derived from a diseased human brain. EMBO J 1987; 6:681-8.
34. Bray M, Hatfill S, Hensley L, Huggins JW. Haematological, biochemical and coagulation changes in mice, guinea-pigs and monkeys infected with a mouse-adapted variant of Ebola Zaire virus. J Comp Pathol 2001; 125:243-53.
35. Chang WL, Tarantal AF, Zhou SS, Borowsky AD, Barry PA. A recombinant rhesus cytomegalovirus expressing enhanced green fluorescent protein retains the wild-type phenotype and pathogenicity in fetal macaques. J Virol 2002; 76:9493-504.
36. Alexander L, Veazey RS, Czajak S, et al. Recombinant simian immunodeficiency virus expressing green fluorescent protein identifies infected cells in rhesus monkeys. AIDS Res Hum Retroviruses 1999; 15:11-21.
37. von Messling V, Svitek N, Cattaneo R. Receptor (SLAM [CD150]) recognition and the V protein sustain swift lymphocyte-based invasion of mucosal tissue and lymphatic organs by a morbillivirus. J Virol 2006; 80:6084-92.
38. Duprex WP, McQuaid S, Roscic-Mrkic B, Cattaneo R, McCallister C, Rima BK. In vitro and in vivo infection of neural cells by a recombinant measles virus expressing enhanced green fluorescent protein. J Virol 2000; 74:7972-9.
39. Gibb TR, Bray M, Geisbert TW, et al. Pathogenesis of experimental Ebola Zaire virus infection in BALB/c mice. J Comp Pathol 2001; 125:233-42.
40. Warfield KL, Panchal RG, Aman MJ, Bavari S. Antisense treatment for biothreat agents [review]. Curr Opin Mol Ther 2006; 8:93-103.
41. Enterlein S, Warfield KL, Swenson DL, et al. VP35 knockdown inhibits Ebola virus amplification and protects against lethal infection in mice. Antimicrob Agents Chemother 2006; 50:984-93.
42. Geisbert TW, Hensley LE, Kagan E, et al. Postexposure protection of guinea pigs against a lethal Ebola virus challenge is conferred by RNA interference. J Infect Dis 2006; 193:1650-7.
43. Warfield KL, Swenson DL, Olinger GG, et al. Gene-specific countermeasures against Ebola virus based on antisense phosphorodiamidate morpholino oligomers. PLoS Pathog 2006; 2:e1.
44. Hensley LE, Jones SM, Feldmann H, Jahrling PB, Geisbert TW. Ebola and Marburg viruses: pathogenesis and development of countermeasures [review]. Curr Mol Med 2005; 5:761-72.
45. Connolly BM, Steele KE, Davis KJ, et al. Pathogenesis of experimental Ebola virus infection in guinea pigs. J Infect Dis 1999; 179(Suppl 1):S203-17.
46. Volchkov VE, Chepurnov AA, Volchkova VA, Ternovoj VA, Klenk HD. Molecular characterization of guinea pig-adapted variants of Ebola virus. Virology 2000; 277:147-55.